How will we treat breast cancer 10 years from now?

Paolo Tarantino shared an article by Mattea Reinisch et al. on LinkedIn:          .

“How to sequence ADCs? Which adjuvant CDK4/6 inhibitor to use between abemaciclib and ribociclib? How will we treat breast cancer 10 years from now?

Fun and insightful post – ASCO discussion, chaired by Mattea Reinisch, now published on Breast Care.

Open Access link.”

Source: Paolo Tarantino/LinkedIn

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.